Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Mutual Advisors LLC

Mutual Advisors LLC cut its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 36.5% during the 3rd quarter, Holdings Channel.com reports. The firm owned 54,652 shares of the biopharmaceutical company’s stock after selling 31,402 shares during the quarter. Mutual Advisors LLC’s holdings in Bristol-Myers Squibb were worth $2,892,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. ESL Trust Services LLC acquired a new stake in Bristol-Myers Squibb in the first quarter valued at $27,000. ORG Wealth Partners LLC bought a new stake in shares of Bristol-Myers Squibb in the 3rd quarter worth about $34,000. LGT Financial Advisors LLC raised its stake in shares of Bristol-Myers Squibb by 42.7% in the 2nd quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 227 shares in the last quarter. MFA Wealth Advisors LLC bought a new position in shares of Bristol-Myers Squibb during the second quarter worth about $39,000. Finally, Beach Investment Counsel Inc. PA acquired a new position in Bristol-Myers Squibb in the second quarter worth about $42,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have commented on BMY. TD Cowen increased their target price on Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Barclays raised their price objective on Bristol-Myers Squibb from $42.00 to $43.00 and gave the stock an “underweight” rating in a research note on Monday, October 7th. Jefferies Financial Group increased their target price on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a report on Wednesday, August 28th. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a research report on Tuesday, July 23rd. Finally, Citigroup downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their target price for the company from $75.00 to $55.00 in a research note on Friday, October 25th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $52.38.

Bristol-Myers Squibb Stock Up 0.3 %

Shares of BMY stock opened at $52.68 on Thursday. The company has a debt-to-equity ratio of 2.86, a quick ratio of 1.02 and a current ratio of 1.16. The stock has a market cap of $106.79 billion, a PE ratio of -16.99, a price-to-earnings-growth ratio of 13.75 and a beta of 0.46. The business’s fifty day moving average is $50.98 and its 200-day moving average is $46.48. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $55.03.

Bristol-Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be paid a $0.60 dividend. The ex-dividend date is Friday, October 4th. This represents a $2.40 annualized dividend and a dividend yield of 4.56%. Bristol-Myers Squibb’s dividend payout ratio is currently -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.